FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Antiemetic Drugs Market Overview:

According to FutureWise analysis, the market for Antiemetic drugs is estimated to be US$ 8.17 billion in 2023 and is expected to reach US$ 13.29 billion in 2031 at a CAGR of 6.30%.

Antiemetic drugs play a crucial role in alleviating nausea and vomiting, symptoms that can arise from various sources, including medical conditions, treatments, procedures, and medications. These medications are available in diverse forms, including tablets, sublingual, oral solutions, suppositories, transdermal patches, or intravenous injections, catering to individual preferences and conditions. Several classes of antiemetic drugs are employed to address these symptoms. 5-HT3 receptor antagonists, like ondansetron, are effective against acute gastroenteritis and postoperative nausea, as well as common side effects of radiotherapy and chemotherapy. Dopamine antagonists such as metoclopramide and domperidone are widely used for postoperative nausea and motion sickness. H1 antihistamines and antimuscarinics like scopolamine effectively treat vestibular-induced nausea and vomiting, with transdermal patches offering a convenient delivery method. Glucocorticoids are indicated for chemotherapy-induced emesis, while neurokinin 1 (NK-1) receptor antagonists such as aprepitant are relatively new options for managing chemotherapy and radiotherapy-induced symptoms.

They determine the most effective antiemetic hinges on a comprehensive assessment by a healthcare professional, factoring in the specific context, severity, and underlying cause. The choice of medication should be tailored to the individual's needs, medical history, and potential side effects. Given the diverse array of antiemetic medications, medical expertise should guide appropriate selection to ensure optimal symptom relief while minimizing adverse effects. Possible side effects of antiemetic drugs include headache, fatigue, dizziness, dry mouth, and changes in bowel habits. The careful selection of the proper antiemetic medication is best made in consultation with a qualified healthcare provider, considering the patient's unique circumstances, the severity and origin of the symptoms, and any coexisting medical conditions or medications.

FutureWise Market Research has published a report that provides an insightful analysis of Antiemetic Drugs Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Antiemetic Drugs Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

Major players included in the Antiemetic Drugs Market:

Baxter International
Novartis AG
Johnson and Johnson
GlaxoSmithKline Plc
Cipla Ltd.
Pfizer Inc.
Astellas Pharma
Merck
Sanofi-Aventis
Abbott Labs

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Development in Antiemetic Drugs Market:

In April 2022, the U.S. Food and Drug Administration (FDA) granted Evoke Pharma, Inc. new drug product exclusivity for Gimoti (metoclopramide) nasal spray. This exclusivity provides Evoke with exclusive marketing rights for three years starting from the initial approval date, safeguarding the product against competition from generic drugs under the provisions of the Hatch-Waxman Act. Metoclopramide, a dopamine antagonist, serves as a potent antiemetic medication.
In February 2022, Acacia Pharmaceuticals received FDA approval for Barhemsys, an intravenous formulation of amisulpride, a dopamine antagonist. Barhemsys is designed to address postoperative Vomiting and nausea in patients who have not responded to antiemetic treatment from a different class. Acacia Pharmaceuticals is preparing for a commercial launch and anticipates introducing Barhemsys in the latter half of 2022.

The anti-emetic drugs market is propelled by several influential drivers, creating a landscape of opportunities and challenges that shape its trajectory. A significant driver is the increase in prevalence of cancer, especially the widespread occurrences of breast and lung cancers. These malignancies contribute to a substantial number of global deaths annually and are often treated with chemotherapy, which frequently induces distressing side effects like nausea and vomiting. This underscores the pressing need for effective anti-emetic drugs to alleviate these symptoms and enhance patients' quality of life. Furthermore, the rising allocation of healthcare expenditures and the concurrent development of healthcare infrastructure globally provide a fertile ground for market growth. Governments and healthcare entities across regions actively invest in enhancing healthcare services and facilities, facilitating better patient access to anti-emetic treatments. The aging population and increasing awareness of healthcare options and advancements further boosts the market's potential. Amid these driving forces, opportunities emerge on multiple fronts. Strategic collaborations between established pharmaceutical giants and innovative biotech firms promise to accelerate research and development efforts, yielding novel anti-emetic treatments and expanding the market's horizons. Additionally, the exploration of emerging markets and the continuous investment in research and development activities hold the potential to unearth new avenues for growth.

However, the market encounters its share of challenges and constraints. Adverse effects of certain anti-emetic drugs, including dopamine antagonists causing anticholinergic symptoms, present a hurdle to broader adoption. These side effects may deter patients and healthcare professionals from embracing such treatments, potentially impacting market expansion. Moreover, drug development's high costs and complex regulatory landscape pose substantial challenges. The lengthy and resource-intensive process of obtaining regulatory approvals and bringing new anti-emetic drugs to market can hinder innovation and market entry. In some developing economies, a lack of robust healthcare infrastructure and a shortage of skilled healthcare professionals may impede the effective distribution and administration of anti-emetic drugs. Additionally, limited awareness among patients and healthcare providers about the benefits of anti-emetic medications and the presence of stringent government regulations may constrain market growth in certain regions.

Antiemetic Drugs Market Segmentation:

By Type of Drug

5-HT3 receptor antagonists
Dopamine antagonists
Steroid-Corticosteroids
Benzodiazepines
NK1 receptor antagonist
Antihistamines
Cannabinoids
Anticholinergic
Others

By Application

Chemotherapy
Pregnancy
Motion Sickness
Food Poisoning
Gastroenteritis
Dizziness
General Anesthetics
Opioid Analgesics
Emotional Stress
Others

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America maintains its dominant position in the antiemetic drugs market and is projected to sustain this leadership throughout the forecast period. This supremacy is attributed to the increasing prevalence of cancer and a rise in healthcare spending, which are anticipated to drive the market's growth trajectory in this region. Moreover, the presence of prominent industry players and the adoption of advanced technologies are expected to contribute to the market's expansion in North America. The Asia-Pacific region is poised to exhibit the most rapid growth during the forecast period from 2022 to 2029. This growth can be attributed to a rising level of disposable income within the region. Furthermore, the development of healthcare infrastructure and an increasing number of manufacturers producing generic drugs are expected to propel the market's growth in the Asia-Pacific region.

Competitive Landscape:

Tier 1 players-established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the of Antiemetic Drugs Market By Type of Drug, By Application, By Region.
To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
To evaluate current market trends and forecast micro-markets and the overall market projections which are represents in format of data-sets and ppt.
To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1. Years Considered for the Study
  3.2. Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1 . Secondary Data
  1.1.1. Key Data from Secondary Sources
  1.2 . Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Antiemetic Drugs Market Variables, Trends and Scope
- 1. Market Lineage Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Technology Overview
  6. Regulatory Framework
  6.1. Reimbursement Framework
  6.2. Standards and Compliances
5. Market Overview
- 1. Market Dynamics
  1.1. Market Driver Analysis
  1.1.1. Increasing focus of Antiemetic Drugs Companies on Brand Protection
  1.1.2. Untapped Opportunities in Emerging Regions
  1.2. Market Restraint Analysis
  1.2.1. High Cost Associated with Implementation of Predictive Analysis
  1.3. Industry Challenges
  1.3.1. Presence of Ambiguous Regulatory Framework
6. Antiemetic Drugs Market Analysis Tools
- 1. Industry Analysis - Porter’s
  1.1. Supplier Power
  1.2. Buyer Power
  1.3. Substitution Threat
  1.4. Threat from New Entrants
  1.5. Competitive Rivalry
  2. Pestel Analysis
  2.1. Political Landscape
  2.2. Environmental Landscape
  2.3. Social Landscape
  2.4. Technology Landscape
  2.5. Legal Landscape
  3. Major Deals And Strategic Alliances Analysis
  3.1. Joint Ventures
  3.2. Mergers and Acquisitions
  3.3. Licensing and Partnership
  3.4. Technology Collaborations
  3.5. Strategic Divestments
  4. Market Entry Strategies
  5. Case Studies
7. Antiemetic Drugs Market, By Type of Drug Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. 5-HT3 receptor antagonists
  2. Dopamine antagonists
  3. Steroid-Corticosteroids
  4. Benzodiazepines
  5. NK1 receptor antagonist
  6. Antihistamines
  7. Cannabinoids
  8. Anticholinergic
  9. Others
8. Antiemetic Drugs Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Chemotherapy
  2. Pregnancy
  3. Motion Sickness
  4. Food Poisoning
  5. Gastroenteritis
  6. Diziness
  7. General Anesthetics
  8. Opiod Analgesics
  9. Emotional Stress
  10. Others
9. North America Antiemetic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  3. Market Size (USD Million) Forecast for North America 2023-2031
10. Latin America Antiemetic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Brazil
  2.2. Venezuela
  2.3. Argentina
  2.4. Rest of Latin America
  3. Market Size (USD Million) Forecast for Latin America 2023-2031
11. Europe Antiemetic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5. Spain
  2.6. Russia
  2.7. Poland
  2.8. Rest of Europe
  3. Market Size (USD Million) Forecast for Europe 2023-2031
12. Asia Pacific Antiemetic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Japan
  2.2. China
  2.3. India
  2.4. Australia and New Zealand
  2.5. ASEAN
  2.6. Rest of Asia Pacific
  3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031
13. Middle East and Africa Antiemetic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. GCC
  2.2. Israel
  2.3. South Africa
  2.4. Rest of MEA
  3. Market Size (USD Million) Forecast for MEA 2023-2031
14. Market Share Analysis and Competitive Landscape
- 1. Global Landscape - Key Players, Revenue and Presence
  2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
  3. Global Emerging Companies
  4. North America - Market Share Analysis and Key Regional Players
  5. Europe - Market Share Analysis and Key Regional Players
  6. Asia Pacific - Market Share Analysis and Key Regional Players
  7. Global Key Player - Growth Matrix
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
- 1. Baxter International
  1.1. Company Overview
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. Novartis AG
  2.1. Company Overview
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. Johnson and Johnson
  3.1. Company Overview
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. GlaxoSmithKline Plc
  4.1. Company Overview
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  5. Cipla Ltd.
  5.1. Company Overview
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  6. Pfizer Inc.
  6.1. Company Overview
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
  7. Astellas Pharma
  7.1. Company Overview
  7.2. Product Portfolio
  7.3. SWOT Analysis
  7.4. Financial Overview
  7.5. Strategic Overview
  8. Merck
  8.1. Company Overview
  8.2. Product Portfolio
  8.3. SWOT Analysis
  8.4. Financial Overview
  8.5. Strategic Overview
  9. Sanofi-Aventis
  9.1. Company Overview
  9.2. Product Portfolio
  9.3. SWOT Analysis
  9.4. Financial Overview
  9.5. Strategic Overview
  10. Abbott Labs
  10.1. Company Overview
  10.2. Product Portfolio
  10.3. SWOT Analysis
  10.4. Financial Overview
  10.5. Strategic Overview
16. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the healthcare regulations initiated by
  administrations
  5. The overall economic slowdown of the developing and developed nations
17. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients